Showing results (61-70 of 161) with videos related to

Sort By:
Pageof 17
BJU International|June 30, 2009
Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TURAnna Orsola, Lluís Cecchini, Carles X Raventós, et al.
Journal of Personalized Medicine|February 23, 2024
Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate CancerJuan Morote, Ángel Borque-Fernando, Luis M Esteban, et al.
BJU International|January 13, 2011
Prostate cancer in Spain: from guidelines to clinical practiceAntonio Alcaraz, Francisco J Burgos, José M Cózar, et al.
BMC Cancer|April 3, 2022
Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic reviewMercè Cuadras, Jacques Planas, Ana Celma, et al.
Archivos Espanoles De Urologia|April 30, 2009
[Closure of a neobladder-vaginal fistula in a patient with Studer's type neobladder using a transvaginal approach with interposition of a Martius' flap]Juan E Bestard Vallejo, Anna Orsola de los Santos, Carles X Raventós Busquets, et al.
BJU International|November 13, 2010
Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcomeMaria Carmen Mir, Enrique Trilla, Ines Maria de Torres, et al.
European Urology Oncology|August 15, 2019
Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?Juan Morote, Anna Celma, Sarai Roche, et al.
International Journal of Molecular Sciences|August 8, 2014
Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressivenessJuan Morote, Anna Celma, Jacques Planas, et al.
BJU International|May 9, 2013
Role of immunotherapy in castration-resistant prostate cancer (CRPC)Cristina Suárez, Rafael Morales-Barrera, Victor Ramos, et al.
BJU International|August 18, 2009
Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer riskJuan Morote, Jacques Planas, Cristobal Ramirez, et al.
Pageof 17